Video Panel: How China Inc. Sells Latest Therapies In An Untapped Market
Top Execs Discuss If Country Can Become True Global Player
Executive Summary
During the “Road to Commercialization” panel session during EBD/Informa Connect's recent annual ChinaBio partnering event, senior executives from top Chinese biotechs along with a leading contract manufacturing organization and venture fund shared views on biologics commercialization in China. Partnerships to accelerate the process, as well as the future commercial direction of novel biologics in their fastest-growing market worldwide, were also discussed.
You may also be interested in...
How China Inc. Aims To Take Over Cell Therapy Dominance
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
Roche, Sanofi Double Down On Post-Coronavirus China With Oncology Alliances
In a bid widely seen as a move to double down on their “in China for China” strategy, Sanofi and Roche have formed new drug development alliances with local innovative players potentially worth billions.
COVID Unrest, Health Sector Deep Freeze Hits Chinese Biotechs Hard
Much of the biopharma and other health-related industries in China were already feeling the chill from ongoing macro-economic and other headwinds this year, which now look set to be complicated further by the added strain of social unrest over strict COVID containment policies. The combination of factors is already prompting some to take steps towards restructuring and divestments to survive.